Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health HIV testing coverage update | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentOscar HealthPolicy N/A

    Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance Assays

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage and medical necessity criteria for HIV screening, diagnostic testing, viral load monitoring, genotypic and phenotypic resistance testing, and limits for repeat testing; applies to providers submitting claims to Oscar Health.

    Policy Summary
    PayerOscar Health
    PolicyHuman Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance Assays
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionEnsure services meet authorization and medical necessity guidelines and use applicable procedure codes when requesting test authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    11-65Age range for routine screening
    90 daysMin interval: Ab/Ag tests
    1 moMin interval: repeat NAAT
    0.5 log10Biologically relevant RNA change
    >=200 cp/mLVL threshold — resistance testing
    >=500 cp/mLHIV-2 resistance threshold

    Coverage and Medical Necessity Criteria

    Covered indications

    Covered when the following conditions are met:

    Routine screening 11-65: For individuals 11 to 65 years of age, initial screening for HIV infection with an antigen/antibody combination assay MEETS CRITERIA.age 11-65

    See policy III.1

    Repeat screening 11-65: For individuals 11 to 65 years of age, repeat antigen/antibody screening for HIV infection MEETS CRITERIA.see Note 1 for interval limits

    See policy III.2

    PrEP and elevated risk: For individuals who will begin PrEP, are receiving PrEP, or have elevated risk factors for HIV infection, screening with an antigen/antibody combination assay or a rapid antibody test MEETS CRITERIA.
    Policy Summary
    PayerOscar Health
    PolicyHuman Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance Assays
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionEnsure services meet authorization and medical necessity guidelines and use applicable procedure codes when requesting test authorization.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling Codes and Key Numeric ThresholdsAuthorization, Documentation, and Operational Guidance for ProvidersClinical Background and Evidence SummaryDefinitions and Assay DescriptionsPolicy Revision History
    risk factors per Note 2

    See policy III.3

    Confirmatory differentiation assay: For individuals with a positive initial screening, the HIV-1/HIV-2 antibody differentiation assay MEETS CRITERIA.positive initial screen

    See policy III.4

    Nucleic acid testing indications: Nucleic acid testing (qualitative or quantitative) for HIV-1 and HIV-2 MEETS CRITERIA for: a) individuals with a positive initial screening; b) individuals with indeterminate initial screening; c) individuals with suspected or reported recent exposure.as listed

    See policy III.5 a–c

    Genotyping/phenotyping indications: HIV genotyping or phenotyping MEETS CRITERIA for clinical scenarios including: prior to initiating doravirine therapy (required); treatment failure; suboptimal viral load reduction; noncompliance; guiding treatment in acute/recent infection (≤6 months); antiretroviral‑naïve individuals entering treatment; and specified pregnancy situations.as listed

    See policy III.6 a–g

    Phenotyping for multidrug resistance: For treatment‑experienced individuals on failing regimens thought to have multidrug resistance, HIV phenotyping MEETS CRITERIA.treatment‑experienced failing regimen

    See policy III.7

    Not medically necessary / Not covered

    Not covered / does not meet criteria:

    Antibody-only tests without antigen: Screening using an antibody test that does not provide rapid results and does not incorporate antigen testing DOES NOT MEET CRITERIA.

    See policy III.9

    Antigen testing alone: HIV antigen testing independent of antigen/antibody testing DOES NOT MEET CRITERIA.

    See policy III.10

    Routine combined genotyping+phenotyping: Routine use of combined genotyping and phenotyping DOES NOT MEET CRITERIA.

    See policy III.11

    Drug susceptibility prediction via genotypic comparison: Drug susceptibility phenotype prediction using genotypic comparison to known genotypic/phenotypic databases DOES NOT MEET CRITERIA.

    See policy III.12

    Coverage criteria per DHHS guidance

    Covered when following DHHS recommendations for testing and monitoring are met

    Initial evaluation and monitoring: Measure plasma HIV RNA at entry into care and when ART is initiated; repeat 4–8 weeks after initiation and every 4–8 weeks until below assay detection; in stable suppressed patients, measure every 3–4 months and may extend to 6 months if suppressed >1 year and adherent.timing-based

    DHHS: timing for viral load monitoring

    Drug resistance testing - initial: Send genotypic drug‑resistance testing before initiation of ART to guide regimen selection; genotypic testing preferred over phenotypic in ARV‑naïve patients; include integrase gene when transmitted INSTI resistance suspected or prior CAB‑LA PrEP use. Do not delay ART initiation for results when starting same‑day; modify regimen after results available.test-type

    DHHS recommendations

    Drug resistance testing - experienced: Perform resistance testing to assist selection of active drugs when changing ART for persons with virologic failure and HIV RNA >200 copies/mL (graded evidence stronger at higher viral loads); testing should be done while on regimen or within 4 weeks of stopping non‑long‑acting ARVs.>200 copies/mL

    DHHS: AI for >1,000; AIII for 501–1,000; CIII for 201–500

    Pregnancy and perinatal testing: For pregnancy: perform opt‑out testing early in pregnancy, repeat in third trimester when risk elevated or per jurisdictional rules; expedited testing during labor if undocumented; perform antibody differentiation and HIV RNA if positive; test newborn with NAT and initiate presumptive therapy when indicated.clinical-scenario

    DHHS guidance on perinatal testing and newborn management

    Guideline-based coverage criteria — grouped by clinical scenario

    Covered when meeting guideline-based clinical indications described below (grouped by clinical scenario):

    Initial evaluation of ART-naïve patients: Genotypic drug‑resistance testing is recommended at entry into care to guide selection of initial ART; do not delay ART initiation awaiting results; include integrase genotyping if transmitted INSTI resistance is a concern or prior CAB‑LA PrEP use.

    DHHS/IAS/others

    Virologic failure or suboptimal response: Perform drug‑resistance testing for persons with virologic failure and HIV RNA >200 copies/mL (stronger recommendation at higher viral loads); RT and protease genotyping for all; add integrase genotyping if on or with history of INSTI; perform testing while on ART or within 4 weeks after stopping non‑long‑acting drugs.>200 copies/mL

    AI for >1,000; AIII for 501–1,000; CIII for 201–500

    Long‑acting ARV or CAB‑LA PrEP exposure: For virologic failure on long‑acting CAB + rilpivirine or for acquisition of HIV after CAB‑LA PrEP, perform resistance testing (including INSTI) regardless of time since discontinuation due to long drug half‑lives.

    DHHS: long‑acting agents guidance

    Pregnancy-specific testing and delivery planning: Recommend genotypic resistance testing for all pregnant people before ART initiation and for those entering pregnancy with detectable HIV RNA on therapy; check viral load in third trimester and if viral load >=1000 copies/mL near term plan cesarean at 38 0/7 weeks.>=1000 copies/mL

    References: DHHS, ACOG, SMFM

    When to use additional or alternate assays: Use NAT for acute or early infection or when Ag/Ab tests are negative/indeterminate but suspicion remains; consider proviral DNA assays when RNA is undetectable or low and RNA genotyping unlikely to succeed; consider adding phenotypic testing for complex resistance patterns.

    CDC/DHHS/IAS guidance

    Monitoring frequency after ART initiation: Obtain HIV RNA within 2–8 weeks after ART start (IDSA: 2–4 weeks preferred), then every 4–8 weeks until suppression; after suppression and stability, monitoring every 3–6 months (may extend to 6 months or longer per guideline and stability).

    IDSA/International guidance

    HIV-2 testing and monitoring (Initial and ongoing)

    Covered when meeting the following clinical testing and monitoring recommendations for HIV-2:

    Initial investigation for acute/very recent HIV-2: Investigate acute or very recent HIV‑2 infection as for chronic HIV‑2. If a blood sample taken within 3 months of likely exposure is HIV‑2 screening negative, repeat testing at 6 weeks and 3 months with parallel HIV‑2 viral RNA testing and, if necessary, HIV‑2 proviral DNA.

    BHIVA guidance

    Indeterminate serology evaluation: Any HIV‑1 or HIV‑2 serology that does not fit a clear confirmed pattern should be fully investigated for HIV‑2 infection with PCR for HIV‑2 proviral DNA.

    BHIVA recommendation

    HIV‑2 viral load monitoring schedule: If pre‑treatment HIV‑2 viral load was detectable: measure at 1, 3, and 6 months after starting or changing ART, then every 3–6 months. If pre‑treatment viral load was undetectable: measure at 1 month and then every 6 months. Repeat viral load when previously maximally suppressed then becomes detectable.

    BHIVA monitoring guidance

    Resistance testing indications: Perform resistance testing at diagnosis, prior to treatment initiation, and at virological failure if HIV‑2 viral load is ≥ 500 copies/mL.>= 500 copies/mL

    BHIVA: resistance testing threshold

    Screening with an antibody-only test that does not incorporate antigen detection is explicitly listed as not meeting criteria and therefore excluded from coverage. The policy also states that HIV antigen testing performed alone (independent of an antigen/antibody combination assay) does not meet criteria. Providers should order a combination antigen/antibody assay for screening rather than antibody-only or antigen-alone tests to meet coverage requirements.

    A single cost-effectiveness analysis cited in the evidence review found that point-of-care HIV RNA viral load testing to guide mode of delivery for women without prenatal care was more costly and resulted in more HIV-infected neonates compared with routine cesarean delivery for all. The authors concluded the viral-load guided strategy was not cost-effective in that scenario; this finding limits the utility of point-of-care viral load testing as a replacement for routine cesarean delivery in women lacking prenatal care.

    The International Antiviral Society guidance states that proviral resistance testing is not required prior to switching to 2-drug therapy unless there is documented or suspected treatment failure. For patients who have maintained viral suppression, switching from long-acting cabotegravir plus rilpivirine back to oral therapy can be done without proviral DNA resistance testing. If virologic failure is later confirmed, genotype resistance testing should be performed, preferably on the failing regimen or shortly after discontinuation.

    Routine proviral DNA genotyping is not recommended for virologically suppressed persons. Guidance notes that proviral DNA genotypes may fail to detect prior resistance and can identify mutations of uncertain clinical relevance, so use of proviral genotyping in suppressed patients should be selective and interpreted cautiously rather than performed routinely.

    The policy identifies routine combined genotyping plus phenotyping and automated phenotype prediction from genotypic database comparison as not meeting criteria. Phenotypic and genotypic assays both have limited sensitivity for low-level minority variants comprising <1–20% of the viral population, which constrains the value of routine combined testing and algorithmic phenotype prediction in many settings.

    Both phenotypic and genotypic resistance assays have limitations detecting low-frequency variants. The document notes decreased sensitivity for minority variants that represent <1% to 20% of the viral population, meaning assays may miss clinically relevant low-level resistance and that results should be interpreted with awareness of these detection limits.

    IAS guidance affirms that viral load measurement remains the primary laboratory method for baseline evaluation and monitoring, and that proviral resistance testing is not required for routine regimen switches in virologically suppressed patients unless there is documented or suspected failure. The guidance emphasizes performing resistance testing for confirmed virologic failure and considers testing while on failing therapy or soon after discontinuation to maximize yield.

    Billing Codes and Key Numeric Thresholds

    No explicit billing codes in this sectionmixed
    No codes listed
    Covered CPT/HCPCS Codes (antibody & HIV-1 NAAT)mixedCovered
    86701Antibody; HIV-1.
    86702Antibody; HIV-2.
    86703Antibody; HIV-1 and HIV-2, single result.
    87391Infectious agent antigen detection by immunoassay technique, qualitative or semiquantitative; HIV-1.
    87534Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique.
    87535Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed.
    87536Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed.
    Covered CPT Codes (HIV-2 NAAT)CPTCovered
    87537Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique.
    87538Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed.
    87539Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed.
    Covered CPT/HCPCS Codes (resistance/genotype and screening)mixedCovered
    87901Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions.
    87903Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV-1; first through 10 drugs tested.
    87906Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion).
    0219UInfectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (protease, RT, integrase), algorithm reported as prediction of antiviral drug susceptibility (Sentosa® SQ HIV-1 Genotyping Assay).
    G0432Infectious agent antibody detection by enzyme immunoassay (EIA) technique, HIV-1 and/or HIV-2, screening.
    G0433Infectious agent antibody detection by enzyme-linked immunosorbent assay (ELISA) technique, HIV-1 and/or HIV-2, screening.
    G0435Infectious agent antibody detection by rapid antibody test, HIV-1 and/or HIV-2, screening.
    G0475HIV antigen/antibody, combination assay, screening.
    S3645HIV-1 antibody testing of oral mucosal transudate.
    inv-17: Biologically relevant change in HIV-1 RNA
    Biologically relevant change>= 0.5 log10 (approximately threefold change in HIV-1 RNA)
    ReasoningChanges smaller than 0.5 log10 may reflect assay variability or transient biologic events (e.g., intercurrent illness, vaccination)
    Clinical implicationUse ≥0.5 log10 change to distinguish meaningful virologic change from assay noise when monitoring ART response
    inv-18: Assay agreement threshold referenced
    Assay agreement threshold200 copies/mL
    ContextThreshold improves inter-assay agreement and aligns with guideline definition of virologic failure
    Implication for testingConsider 200 copies/mL when interpreting low-level viremia across different quantitative assays
    inv-19: Low-positive quantitative HIV RNA repeat threshold
    Low-positive repeat threshold<3,000 copies/mL — repeat quantitative HIV RNA on a new specimen to confirm diagnosis
    RationaleOlder assays produced false-positives <3,000 copies/mL; modern assays detect true acute infection even at low levels, so confirmation on a new specimen is recommended
    ActionWhen low-positive result <3,000 copies/mL with negative/indeterminate antibody test, perform repeat RNA testing and consider qualitative/quantitative testing to confirm acute infection
    inv-20: PrEP-related immediate ART threshold
    PrEP-related immediate ART thresholdHIV RNA >= 200 copies/mL — recommend immediate initiation of effective HIV treatment while awaiting confirmation (AIII)
    Low-positive guidance on PrEPIf very low-positive (<200 copies/mL) in persons on PrEP with negative antibody test, obtain confirmatory antibody and repeat quantitative RNA before initiating ART
    Diagnostic stepCollect a new blood specimen to verify diagnosis prior to initiating treatment when possible; however, start ART promptly if RNA >=200 copies/mL
    inv-21: Resistance testing virologic failure threshold (DHHS categories)
    Virologic failure threshold for resistance testing>200 copies/mL (AI for >1,000; AIII for 501–1,000; CIII for confirmed 201–500)
    Testing at lower VLsTesting may be unsuccessful at lower VLs but should still be considered for confirmed 201–500 copies/mL
    Gene targetsStandard genotypic testing includes reverse transcriptase and protease; add integrase genotyping when transmitted INSTI resistance suspected or prior CAB-LA PrEP use
    inv-22: Viral load threshold for resistance testing (recommended tiers)
    Recommended viral load threshold>200 copies/mL recommended for resistance testing
    Evidence grading by strataAI for >1,000 copies/mL; AIII for 501–1,000 copies/mL; CIII for confirmed 201–500 copies/mL
    TimingPerform resistance testing while on ARVs or within 4 weeks after stopping non–long-acting ARVs; longer intervals may miss selected mutations
    inv-23: Resistance testing viral load threshold (HIV-2 specific)
    HIV-2 resistance testing threshold>= 500 copies/mL — perform resistance testing at diagnosis, prior to treatment initiation, and at virological failure if viral load meets this threshold
    Availability noteQuantitative HIV-2 RNA testing is not widely commercially available; consider proviral DNA PCR when appropriate
    Clinical implicationBecause HIV-2 plasma viremia is often low, use threshold >=500 copies/mL to guide when resistance testing is informative
    inv-24: Aptima HIV-1 Quant assay dynamic/reportable range
    Aptima HIV-1 Quant reportable range30 to 10,000,000 copies/mL
    FDA statusFDA-approved (2016) for quantitation of HIV-1 RNA groups M, N, and O on the Panther system; approved for diagnosis and viral load monitoring (dual use as of Nov 20, 2020)
    Clinical useSuitable for quantifying HIV-1 RNA across a broad dynamic range for diagnosis and monitoring of ART response

    Authorization, Documentation, and Operational Guidance for Providers

    Prior Authorization

    Authorization and medical necessity

    Services must meet authorization and medical necessity guidelines and the member's benefit coverage at the time of request; coverage does not guarantee reimbursement.

    Prior Authorization

    Obtain genotypic resistance testing at entry to care and for virologic failure

    Send genotypic drug-resistance testing at entry into care to guide initial ART selection and perform resistance testing for persons with virologic failure; ensure genotypic testing includes integrase when transmitted INSTI resistance is suspected or prior CAB-LA PrEP use.

    • Do not delay ART initiation for results when starting same-day; modify regimen after results are available.
    • For virologic failure, perform testing for HIV-RNA >200 copies/mL (stronger evidence at higher viral loads).
    Note

    Prior authorization — none specified

    No explicit prior authorization requirements are stated in the referenced policy excerpts.

    Billing Rule

    Use listed CPT/HCPCS codes for test authorization

    Use the listed CPT/HCPCS procedure codes when requesting authorization or submitting claims for HIV antibody/antigen, nucleic acid, and resistance/genotype testing.

    • Examples include 86701–86703 (antibody), 87534–87536 (HIV-1 NAAT), 87537–87539 (HIV-2 NAAT), and 87901/87906/0219U (genotype).
    • Also include screening codes G0432–G0435 and combination assay code G0475 as applicable.
    Note

    Prior authorization not specified in this section

    No prior authorization requirements are specified in these reference excerpts.

    Note

    Provider actions — order tests per coverage criteria and document rationale

    Providers must follow policy coverage criteria and guideline-based indications when ordering tests and document clinical rationale in the medical record.

    • Order tests consistent with indicated scenarios (e.g., screening, confirmatory differentiation, NAT for indeterminate/acute cases, genotyping for treatment failure).
    Step Therapy

    Viral load monitoring timeline per DHHS

    Follow DHHS viral-load monitoring schedule: measure at baseline/when ART is initiated, at 4–8 weeks after initiation, then every 4–8 weeks until below detection; once suppressed and stable, monitor every 3–4 months (may extend to 6 months if suppressed >1 year and adherent).

    • If changing ART for virologic failure, measure before change and 4–8 weeks after the modification, then every 4–8 weeks until suppressed.
    Note

    Proviral resistance testing not routinely required before 2‑drug switches

    Per IAS guidance, proviral resistance testing is not required before switching to two‑drug therapy unless there is documented or suspected treatment failure.

    • If virologic failure is confirmed, perform genotype resistance testing preferably while on the failing regimen.
    Note

    Resistance testing and HBV/HIV co‑infection guidance

    Perform genotypic resistance testing at diagnosis and at virological failure in persons with HBV/HIV coinfection; ensure ART includes TDF or TAF unless there is tenofovir intolerance.

    • Genotypic testing should guide ART selection; do not delay ART initiation while awaiting results.
    Note

    Step therapy — none specified

    No step therapy rules are included in the extracted document parts.

    Documentation Required

    Claims documentation responsibility and coding accuracy

    Providers are responsible for submitting accurate documentation of services performed and for appropriate coding according to standard coding guidelines; failure to follow coding/billing or reimbursement policies may lead to denial or recoupment.

    • Ensure submitted CPT/HCPCS, ICD‑10, and other codes reflect the services performed and clinical indications.
    Documentation Required

    Document quantitative RNA and antibody differentiation for peripartum evaluations

    When diagnosing HIV or evaluating peripartum exposures, document quantitative HIV RNA testing and HIV‑1/HIV‑2 antibody differentiation; maternal HIV test results should be recorded in the newborn record and communicated to the infant's primary care provider.

    • If maternal results are positive or unavailable at birth, perform infant NAT and initiate presumptive therapy as indicated.
    Documentation Required

    Review prior and current resistance results when designing new regimens

    Review and consider all prior and current drug‑resistance test results when constructing a new antiretroviral regimen.

    Documentation Required

    Testing/monitoring documentation for suspected acute HIV‑2 or recent exposure

    For suspected acute HIV‑2 or very recent exposure, if screening was negative within 3 months of exposure, retest at six weeks and three months with parallel HIV‑2 viral RNA and, if necessary, HIV‑2 proviral DNA; repeat HIV‑2 viral load per schedule after ART initiation or change.

    • If pre‑treatment HIV‑2 viral load was detectable: measure at 1, 3, and 6 months after starting/changing ART, then every 3–6 months.
    • If pre‑treatment HIV‑2 viral load was undetectable: measure at 1 month then every 6 months.
    Note

    Reference list — informational only

    The policy's reference list provides supporting literature for clinical recommendations but does not itself establish authorization requirements.

    Denial Risk

    Denial risk for noncompliant coding/billing

    Claims may be denied or recouped if appropriate coding/billing guidelines or current reimbursement policies are not followed; ensure documentation supports the clinical indication for testing.

    Denial Risk

    Resistance testing may fail at low RNA levels — consider timing

    Genotypic resistance testing may be unsuccessful at lower HIV‑RNA levels; despite potential failure, testing should still be considered in confirmed virologic failure (noted for >500 copies/mL may fail but is still recommended).

    • For virologic failure, testing is recommended for HIV‑RNA >200 copies/mL with graded evidence by viral-load strata; testing may be unsuccessful at lower levels but remains advisable.
    Note

    No explicit denial triggers in these sections

    No explicit payer-side denial triggers were specified in the extracted policy excerpts.

    Prior Authorization

    HIV‑2 resistance testing threshold (≥500 copies/mL)

    Perform resistance testing for HIV‑2 when the viral load meets the recommended threshold of ≥500 copies/mL; testing below that threshold may not meet recommended indications.

    Note

    Reference list does not define denial triggers

    No denial triggers are specified in the policy's reference list section.

    Clinical Background and Evidence Summary

    Human immunodeficiency virus is an RNA retrovirus that infects CD4+ T lymphocytes and can lead to progressive immunodeficiency and AIDS; HIV‑1 is the predominant global subtype while HIV‑2 is less common, typically associated with lower plasma viremia and slower clinical progression. Viral load (nucleic acid testing) is used for early detection, monitoring response to antiretroviral therapy, and assessing transmission risk, and resistance testing (genotypic and phenotypic) guides regimen selection and management in treatment failure.

    Definitions and Assay Descriptions

    inv-46: Definition — HIV
    DefinitionHIV is an RNA retrovirus that infects CD4 cells, leading to progressive immune deterioration and potentially AIDS
    SubtypesHIV-1 is the dominant global subtype; HIV-2 is less common and regionally important (e.g., West Africa)
    Clinical consequencesProgressive CD4 decline increases susceptibility to opportunistic infections and HIV-related malignancies
    inv-47: Definition — HIV-2
    DefinitionHIV-2 is a distinct HIV subtype characterized by slower clinical progression, longer asymptomatic stage, and lower plasma viremia compared with HIV-1
    Diagnostic and treatment implicationsHIV-2 is intrinsically resistant to some drug classes (e.g., NNRTIs, enfuvirtide) and quantitative HIV-2 assays are limited in availability; HIV-1 assays may not reliably detect HIV-2
    EpidemiologyEndemic in West Africa; cases reported elsewhere may be underestimated due to detection limitations
    inv-48: Definition — Genotypic assay
    DefinitionGenotypic assay: sequencing-based test that detects specific resistance mutations in HIV genes (protease, reverse transcriptase, integrase) to infer drug resistance
    UtilityPreferred for most clinical scenarios, faster and less costly than phenotypic assays; interpretation may use rule-based systems or expert review
    LimitationsMay miss minority variants and complex interactions of multiple mutations affecting phenotype
    inv-49: Definition — Phenotypic assay
    DefinitionPhenotypic assay: measures the extent to which an antiretroviral drug inhibits a patient's virus (typically reported as fold-change in susceptibility)
    UtilityHelpful for complex or uncertain genotypic patterns where actual drug susceptibility is unclear
    LimitationsLonger turnaround, higher cost, and may have biologic cut-offs above achievable drug levels; limited sensitivity for low-frequency variants
    inv-50: Definition — NAT (Nucleic Acid Test)
    DefinitionNAT (Nucleic Acid Test): a test that detects HIV RNA in blood; used for early detection of infection and to quantify viral load
    Window periodA NAT can usually detect HIV 10–33 days after exposure, earlier than antigen/antibody tests
    Clinical rolesUsed for diagnosis of acute infection, confirmation of reactive antibody screens, and monitoring of viral load during therapy
    inv-51: Definition — Genotypic resistance testing
    DefinitionGenotypic resistance testing: sequencing-based assays to detect mutations in RT, protease, and—when indicated—integrase genes to guide antiretroviral selection
    Preferred useGenerally preferred over phenotypic testing for initial and most clinical resistance evaluations; include integrase testing when INSTI resistance suspected
    TimingShould be performed at diagnosis and at virologic failure (see viral load thresholds); perform while on ARV regimen or within 4 weeks of stopping non-long-acting ARVs
    inv-52: Definition — HIV-2 proviral DNA PCR
    DefinitionHIV-2 proviral DNA PCR: PCR assay detecting integrated HIV-2 DNA used to establish presence/absence of HIV-2 when serology is indeterminate
    Use caseRecommended for investigation of indeterminate HIV-1 or HIV-2 serology to confirm HIV-2 infection
    Clinical noteUseful because quantitative HIV-2 RNA assays are limited and plasma viremia may be low in HIV-2 infection
    inv-53: Definition — FDA-approved HIV assays (examples and reportable ranges)
    Examples of FDA-approved assaysCOBAS AmpliPrep/COBAS TaqMan HIV-1; Aptima HIV-1 Quant Assay; Geenius HIV-1/2 Supplemental Assay; BioPlex 2200 HIV Ag-Ab; Alinity m HIV-1
    Aptima reportable rangeAptima HIV-1 Quant: 30 to 10,000,000 copies/mL (FDA-approved for quantitation and dual use)
    Intended usesAssays cited are used for screening (Ag/Ab), differentiation (Geenius), and quantitative viral load monitoring (COBAS, Aptima, Alinity)
    inv-54: ViroSeq / assay references (manufacturer and FDA docs)
    ViroSeq referenceThermoFisher ViroSeq HIV-1 Genotyping System (manufacturer documentation referenced)
    PurposeCommercial genotyping system used to detect HIV-1 mutations associated with antiretroviral resistance
    Supporting docsManufacturer and FDA documentation cited in references for performance and interpretation details
    inv-55: Guidelines referenced (DHHS, CDC, IAS-USA, BHIVA, EACS, ACOG, AAP)
    Guidelines referencedDHHS, CDC, IAS-USA, BHIVA, EACS, ACOG, AAP
    RoleThese guideline sources inform recommendations on testing indications, monitoring frequency, resistance testing thresholds, and pregnancy/perinatal management
    Document citationsSpecific guideline documents and versions are listed in the references section (see DHHS, CDC, IAS-USA, BHIVA, EACS, AAP entries)

    Policy Revision History

    2026-10-01effective_dateLatest

    Policy effective date set to 2026-10-01.

    2026-06-16last_review

    Policy last reviewed on 2026-06-16.

    Policy effective date: 2026-10-01. Last review date: 2026-06-16.